Qiheshengke Biotechnology
齐禾生科
Qiheshengke Biotechnology (齐禾生科) is a Suzhou-based gene-editing company co-founded in 2021 by chief scientist Caixia Gao and CEO/CTO Kevin Zhao, built around a proprietary SEEDIT™ platform for developing novel gene-editing tools and crop breeding applications . The company has raised two funding rounds exceeding 100 million RMB each: a Pre-A round in April 2023 led by Chende Capital with participation from Source Code Capital, Gaorong Ventures, Zhongxin Capital and others ; and an A+ round in May 2026 led by CITIC Agricultural Industry Fund . Gaorong Ventures, which joined the 2023 round, described the team as a "top-tier" gene-editing scientist group pivoting toward agricultural applications in seeds, grains and vegetables . As of late 2024, the company aimed to advance toward becoming a "globally leading biotechnology company" .
AI-generated — may contain errors, please verify.
Coverage
Rong Report | HT Aero, Xiwang, Helixon and Others Close Major Funding Rounds; Moonshot AI and Momenta Release Leading Models
Major Funding + Leading Model + Mass Production
Code Moment | Qiheshengke Biotechnology Closes Over 100 Million RMB Series A+ Round, Embarking on a New Chapter in Gene Editing Commercialization
Source Code Capital participated in J&T Global Express's Pre-A round in 2023 and has continued to support the company ever since.
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
Rongbao | Multiple Products Debut at Shanghai Auto Show, AI Drug Lands Major Licensing Deal, Mingming Henmang and Geekplus Race Toward Hong Kong IPOs
New product launches, major licensing deals, accelerated clinical trials...
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Qihe Biotech Closes Over RMB 200 Million Series A to Accelerate Gene Editing R&D and Commercialization
Develop novel gene-editing technologies to create exceptional biological traits and products.
When a "Top-Tier" Gene-Editing Scientist Team Starts Caring About Seeds, Grains, and Vegetables | Gaorong Ventures
Let harvests be not only nature's gift, but also the fruit of technology.
Chip companies, surgical robots, and consumer tech brands close new funding rounds | Rongbao · June
Notable developments to watch in June.
Chip/Consumer Electronics/Gene Editing Firms Raise New Funding; Quantum Computers, Micro-Display Chips Achieve Global Leadership | Rongbao · April
Targeting international advanced standards.
Qihe Biotech Closes Over 100 Million Yuan Pre-A Round to Accelerate Development and Application of Novel Gene-Editing Technologies
Accelerate the commercialization of gene-edited breeding.
Qiheshengke Biotechnology Raises Over 100 Million RMB in Pre-A Round with Source Code Capital Participation
This round of funding will help Qiheshengke Biotechnology accelerate the commercialization of gene-edited bio-breeding.
